GlassScriptPhysician profile
Elias P Bonaros
NPI 1720067531
$18,461.39
in general payments reported to CMS, 2019-2025
55 companies · $1,818 in 2025
The $1,818 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,589 · 2020: $1,922 · 2021: $2,665 · 2022: $2,182 · 2023: $1,540 · 2024: $2,746 · 2025: $1,818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,104.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,774.75 | 2019-2025 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $1,596.53 | 2019-2025 | |
| Amgen INC. | $1,587.04 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $1,557.74 | 2019-2025 | |
| Abbott Laboratories | $1,498.78 | 2019-2025 | Assurity, Thoratec Heartmate 3 Lvas Implant Kit, Aveir |
| E.R. Squibb & Sons, L.L.C. | $1,414.41 | 2019-2025 | Camzyos, Eliquis |
| Amarin Pharma, INC. | $1,332.38 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $1,138.16 | 2019-2025 | Farxiga, Lokelma, Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $928.76 | 2019-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $594.36 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $537.61 | 2020-2025 | Verquvo, Capvaxive |
| Edwards Lifesciences Corporation | $520.98 | 2020-2025 | Sapien 3 Ultra Resilia |
| Sanofi-Aventis U.S. LLC | $380.33 | 2019-2024 | |
| Novo Nordisk INC | $292.41 | 2019-2024 | Ozempic, Rybelsus |
| Regeneron Healthcare Solutions, INC. | $274.00 | 2019-2025 | Evkeeza |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elias Bonaros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.